The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy

The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy

PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present s...

Full description

Bibliographic Details
Main Authors: Valentina Maria Caso, Simona Sperlongano, Biagio Liccardo, Emanuele Romeo, Sergio Padula, Fortunato Arenga, Antonello D’Andrea, Pio Caso, Paolo Golino, Gerardo Nigro, Vincenzo Russo
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
PCSK9 inhibitors
adherence
lockdown
Online Access:https://www.mdpi.com/2077-0383/11/3/475

Internet

https://www.mdpi.com/2077-0383/11/3/475

Similar Items